OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SVA, BMY, HUM, HZNP, BSX, and represent 18.96% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: SVA (+$350M), XENE (+$20M), MRSN (+$20M), TVTX (+$19M), PGNY (+$18M), IONS (+$17M), Global Blood Therapeutics In (+$13M), REGN (+$13M), ISEE (+$13M), ALXO (+$13M).
- Started 12 new stock positions in KZR, KALV, PGNY, IONS, SRRK, NVAX, EYPT, TVTX, REGN, ISEE. SVA, APLT.
- Reduced shares in these 10 stocks: DXCM (-$77M), PFE (-$61M), IOVA (-$42M), NSTG (-$40M), MRTX (-$36M), ARQT (-$28M), ABBV (-$18M), TBPH (-$17M), RARE (-$17M), ILMN (-$16M).
- Sold out of its positions in ALBO, ASLN, CABA, DXCM, EXAI, Field Trip Health Ord, GLPG, IMAB, ILMN, LABP. NSTG, OWLT.WS, PYXS, RARE.
- Orbimed Advisors was a net buyer of stock by $133M.
- Orbimed Advisors has $5.5B in assets under management (AUM), dropping by -10.52%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 139 positions in its portfolio as reported in the June 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Sinovac Biotech SHS (SVA) | 6.3 | $350M | NEW | 2.7M | 128.55 | |
Bristol Myers Squibb (BMY) | 3.5 | $194M | -3% | 2.5M | 77.00 | |
Humana (HUM) | 3.1 | $171M | -4% | 366k | 468.07 | |
Horizon Therapeutics Pub L SHS (HZNP) | 3.0 | $168M | -4% | 2.1M | 79.76 | |
Boston Scientific Corporation (BSX) | 3.0 | $163M | -5% | 4.4M | 37.27 | |
Turning Point Therapeutics I | 2.7 | $151M | 2.0M | 75.25 | ||
Springworks Therapeutics (SWTX) | 2.7 | $148M | 6.0M | 24.62 | ||
UnitedHealth (UNH) | 2.6 | $144M | -4% | 281k | 513.63 | |
Pfizer (PFE) | 2.6 | $144M | -29% | 2.7M | 52.43 | |
BioMarin Pharmaceutical (BMRN) | 2.6 | $141M | +3% | 1.7M | 82.87 | |
Seagen (SGEN) | 2.4 | $131M | +10% | 738k | 176.94 | |
Abbvie (ABBV) | 2.2 | $123M | -12% | 800k | 153.16 | |
Edgewise Therapeutics (EWTX) | 2.0 | $112M | 14M | 7.96 | ||
Vertex Pharmaceuticals Incorporated (VRTX) | 2.0 | $109M | -3% | 387k | 281.79 | |
Adicet Bio (ACET) | 2.0 | $109M | 7.4M | 14.60 | ||
Sierra Oncology Com New | 2.0 | $108M | 2.0M | 54.99 | ||
Biohaven Pharmaceutical Holding | 1.9 | $105M | 719k | 145.71 | ||
Intuitive Surgical Com New (ISRG) | 1.9 | $104M | -3% | 517k | 200.71 | |
Arcutis Biotherapeutics (ARQT) | 1.8 | $102M | -21% | 4.8M | 21.31 | |
Tricida (TCDA) | 1.8 | $100M | 10M | 9.68 | ||
Edwards Lifesciences (EW) | 1.7 | $96M | -3% | 1.0M | 95.09 | |
Theseus Pharmaceuticals (THRX) | 1.7 | $94M | 17M | 5.53 | ||
Pmv Pharmaceuticals (PMVP) | 1.7 | $94M | -4% | 6.6M | 14.25 | |
Stryker Corporation (SYK) | 1.6 | $88M | -3% | 441k | 198.93 | |
Neurocrine Biosciences (NBIX) | 1.5 | $83M | -2% | 850k | 97.48 | |
Argenx Se Sponsored Adr (ARGX) | 1.3 | $74M | +14% | 194k | 378.88 | |
Mirati Therapeutics (MRTX) | 1.3 | $73M | -33% | 1.1M | 67.13 | |
Global Blood Therapeutics In | 1.2 | $65M | +25% | 2.0M | 31.95 | |
Natera Call Option (NTRA) | 1.2 | $64M | +3% | 1.8M | 35.44 | |
Thermo Fisher Scientific (TMO) | 1.1 | $62M | -5% | 113k | 543.28 | |
Crinetics Pharmaceuticals In (CRNX) | 1.1 | $60M | 3.2M | 18.65 | ||
Compass Therapeutics (CMPX) | 1.1 | $58M | 22M | 2.65 | ||
Evolent Health Cl A (EVH) | 1.0 | $55M | +27% | 1.8M | 30.71 | |
Ikena Oncology Nonvoting | 1.0 | $54M | +2% | 12M | 4.43 | |
Prelude Therapeutics (PRLD) | 1.0 | $52M | 10M | 5.22 | ||
Kinnate Biopharma (KNTE) | 0.9 | $51M | 4.0M | 12.61 | ||
Abcellera Biologics (ABCL) | 0.9 | $47M | +5% | 4.4M | 10.65 | |
Repare Therapeutics Ord (RPTX) | 0.8 | $47M | 3.3M | 13.99 | ||
Keros Therapeutics (KROS) | 0.8 | $46M | 1.7M | 27.63 | ||
Syndax Pharmaceuticals (SNDX) | 0.8 | $45M | +7% | 2.3M | 19.24 | |
Si-bone (SIBN) | 0.8 | $45M | +7% | 3.4M | 13.20 | |
Guardant Health Call Option (GH) | 0.8 | $44M | -18% | 1.1M | 40.34 | |
Gracell Biotechnologies Sponsored Ads (GRCL) | 0.8 | $43M | 7.9M | 5.50 | ||
Mersana Therapeutics (MRSN) | 0.8 | $42M | +88% | 9.0M | 4.62 | |
Xenon Pharmaceuticals (XENE) | 0.7 | $40M | +93% | 1.3M | 30.42 | |
Xtant Med Hldgs Com New (XTNT) | 0.7 | $38M | 73M | 0.52 | ||
Silverback Therapeutics (SPRY) | 0.7 | $37M | 8.7M | 4.24 | ||
Vectivbio Hldg Ord Shs (VECT) | 0.6 | $35M | +21% | 6.5M | 5.40 | |
Alpine Immune Sciences (ALPN) | 0.6 | $35M | 4.1M | 8.51 | ||
Janux Therapeutics (JANX) | 0.6 | $35M | 2.8M | 12.21 | ||
Tenet Healthcare Corp Com New (THC) | 0.6 | $35M | +4% | 656k | 52.56 | |
Chinook Therapeutics (KDNY) | 0.6 | $33M | +33% | 1.9M | 17.49 | |
Vaxcyte (PCVX) | 0.6 | $33M | 1.5M | 21.76 | ||
Aclaris Therapeutics (ACRS) | 0.6 | $33M | +47% | 2.3M | 13.96 | |
Iovance Biotherapeutics (IOVA) | 0.6 | $31M | -57% | 2.8M | 11.04 | |
Verona Pharma Sponsored Ads (VRNA) | 0.4 | $24M | 5.7M | 4.19 | ||
Scpharmaceuticals (SCPH) | 0.4 | $23M | 4.8M | 4.82 | ||
Biogen Idec (BIIB) | 0.4 | $23M | -5% | 112k | 203.94 | |
Tela Bio (TELA) | 0.4 | $21M | 3.0M | 7.01 | ||
Passage Bio (PASG) | 0.4 | $21M | +21% | 8.9M | 2.36 | |
Decibel Therapeutics (DBTX) | 0.4 | $21M | 4.9M | 4.21 | ||
Neuropace (NPCE) | 0.4 | $20M | 4.0M | 4.95 | ||
Rxsight (RXST) | 0.4 | $20M | 1.4M | 14.08 | ||
Meiragtx Holdings (MGTX) | 0.3 | $19M | -24% | 2.5M | 7.57 | |
Travere Therapeutics (TVTX) | 0.3 | $19M | NEW | 772k | 24.23 | |
Progyny (PGNY) | 0.3 | $18M | NEW | 625k | 29.05 | |
Gilead Sciences (GILD) | 0.3 | $18M | 288k | 61.81 | ||
Alx Oncology Hldgs (ALXO) | 0.3 | $18M | +251% | 2.2M | 8.09 | |
Ionis Pharmaceuticals (IONS) | 0.3 | $17M | NEW | 453k | 37.02 | |
Adagio Therapeutics (IVVD) | 0.3 | $17M | 5.1M | 3.28 | ||
Uniqure Nv SHS (QURE) | 0.3 | $16M | -4% | 875k | 18.64 | |
Gh Research Ordinary Shares (GHRS) | 0.3 | $16M | +13% | 1.6M | 9.98 | |
Rapt Therapeutics (RAPT) | 0.3 | $16M | +139% | 866k | 18.25 | |
Ventyx Biosciences (VTYX) | 0.3 | $16M | 1.3M | 12.23 | ||
Amgen (AMGN) | 0.3 | $14M | 57k | 243.29 | ||
Bellus Health Com New (BLU) | 0.2 | $13M | 1.5M | 9.20 | ||
Regeneron Pharmaceuticals (REGN) | 0.2 | $13M | NEW | 22k | 591.13 | |
Iveric Bio (ISEE) | 0.2 | $13M | NEW | 1.4M | 9.62 | |
Ikena Oncology (IKNA) | 0.2 | $13M | 2.9M | 4.43 | ||
Nextcure (NXTC) | 0.2 | $13M | 2.7M | 4.70 | ||
Signify Health Cl A Com (SGFY) | 0.2 | $12M | +44% | 900k | 13.80 | |
Theravance Biopharma (TBPH) | 0.2 | $12M | -57% | 1.4M | 9.06 | |
Bridgebio Pharma Note 2.250% 2/0 (Principal) | 0.2 | $12M | 30M | 0.41 | ||
Vistagen Therapeutics Com New (VTGN) | 0.2 | $12M | +3% | 13M | 0.88 | |
89bio (ETNB) | 0.2 | $12M | 3.7M | 3.22 | ||
Kezar Life Sciences (KZR) | 0.2 | $12M | NEW | 1.4M | 8.27 | |
Milestone Pharmaceuticals (MIST) | 0.2 | $11M | -29% | 1.8M | 6.15 | |
Mereo Biopharma Group Ads (Principal) (MREO) | 0.2 | $11M | -43% | 9.7M | 1.12 | |
Danaher Corporation 5% Conv Pfd B (Principal) (DHR.PB) | 0.2 | $11M | 8.0k | 1323.17 | ||
Gemini Therapeutics | 0.2 | $9.8M | 5.8M | 1.69 | ||
Chemomab Therapeutics Sponsored Ads (CMMB) | 0.2 | $9.5M | 2.6M | 3.70 | ||
Terns Pharmaceuticals (TERN) | 0.2 | $9.4M | 3.8M | 2.48 | ||
Oric Pharmaceuticals (ORIC) | 0.2 | $9.4M | 2.1M | 4.48 | ||
Erasca (ERAS) | 0.2 | $9.3M | 1.7M | 5.57 | ||
Bridgebio Pharma Note 2.500% 3/1 (Principal) | 0.2 | $9.0M | 20M | 0.45 | ||
Jounce Therapeutics (JNCE) | 0.2 | $8.9M | +2% | 2.9M | 3.03 | |
Cullinan Oncology (CGEM) | 0.2 | $8.6M | 671k | 12.82 | ||
Spdr Ser Tr S&p Biotech (XBI) | 0.2 | $8.3M | 112k | 74.27 | ||
Fusion Pharmaceuticals (FUSN) | 0.1 | $8.0M | 3.2M | 2.49 | ||
Aerovate Therapeutics (AVTE) | 0.1 | $7.5M | -6% | 479k | 15.63 | |
Galecto (GLTO) | 0.1 | $7.1M | 4.1M | 1.73 | ||
Synlogic (SYBX) | 0.1 | $6.9M | 6.0M | 1.15 | ||
Corvus Pharmaceuticals (CRVS) | 0.1 | $6.9M | 6.9M | 0.99 | ||
Pulmonx Corp (LUNG) | 0.1 | $6.4M | 435k | 14.72 | ||
Scholar Rock Hldg Corp (SRRK) | 0.1 | $5.9M | NEW | 1.1M | 5.49 | |
Cybin Ord (CYBN) | 0.1 | $5.9M | 11M | 0.56 | ||
Harpoon Therapeutics (HARP) | 0.1 | $5.8M | 3.0M | 1.91 | ||
Mirum Pharmaceuticals (MIRM) | 0.1 | $5.4M | +935% | 280k | 19.46 | |
Imara (IMRA) | 0.1 | $5.4M | 4.4M | 1.22 | ||
Immunocore Hldgs Ads (IMCR) | 0.1 | $4.9M | +2% | 131k | 37.31 | |
Nanostring Technologies Note 2.625% 3/0 (Principal) | 0.1 | $4.9M | 6.0M | 0.81 | ||
Graybug Vision Com Shs (GRAY) | 0.1 | $4.5M | 4.2M | 1.09 | ||
Vor Biopharma (VOR) | 0.1 | $4.1M | 833k | 4.97 | ||
Burning Rock Biotech Sponsored Ads (BNR) | 0.1 | $4.0M | -4% | 1.4M | 2.91 | |
Applied Therapeutics (APLT) | 0.1 | $4.0M | NEW | 4.3M | 0.95 | |
Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $4.0M | 1.6M | 2.52 | ||
Cytomx Therapeutics (CTMX) | 0.1 | $3.9M | 2.1M | 1.83 | ||
Novavax Com New Call Option (NVAX) | 0.1 | $3.9M | NEW | 75k | 51.43 | |
Celldex Therapeutics Com New (CLDX) | 0.1 | $3.0M | -72% | 113k | 26.96 | |
Logicbio Therapeutics | 0.1 | $3.0M | 8.5M | 0.35 | ||
Acutus Medical (AFIB) | 0.1 | $3.0M | 2.6M | 1.12 | ||
Magenta Therapeutics (MGTA) | 0.0 | $2.7M | 2.3M | 1.20 | ||
Oncocyte (OCX) | 0.0 | $2.6M | -18% | 2.8M | 0.90 | |
Protara Therapeutics Com Stk (TARA) | 0.0 | $2.4M | 831k | 2.93 | ||
Graphite Bio (GRPH) | 0.0 | $2.3M | -45% | 848k | 2.75 | |
9 Meters Biopharma | 0.0 | $2.2M | -17% | 8.5M | 0.26 | |
Singular Genomics Systems In (OMIC) | 0.0 | $2.1M | -76% | 541k | 3.82 | |
Chardan Healthcare Acqu- Ord (PHGE) | 0.0 | $2.1M | 2.8M | 0.73 | ||
Kalvista Pharmaceuticals (KALV) | 0.0 | $1.8M | NEW | 185k | 9.84 | |
Sight Sciences (SGHT) | 0.0 | $1.8M | 200k | 8.99 | ||
Eyepoint Pharmaceuticals Com New (EYPT) | 0.0 | $1.7M | NEW | 214k | 7.87 | |
Sarepta Therapeutics (SRPT) | 0.0 | $1.5M | -48% | 20k | 74.95 | |
X4 Pharmaceuticals (XFOR) | 0.0 | $1.3M | 1.4M | 0.97 | ||
Sonendo (SONX) | 0.0 | $1.2M | -63% | 724k | 1.72 | |
Talaris Therapeutics (TALS) | 0.0 | $1.1M | -4% | 236k | 4.51 | |
Vigil Neuroscience (VIGL) | 0.0 | $1.1M | 411k | 2.58 | ||
Aeglea Biotherapeutics (AGLE) | 0.0 | $908k | -39% | 1.8M | 0.51 | |
Longboard Pharmaceuticals In (LBPH) | 0.0 | $351k | 114k | 3.09 | ||
Aptinyx (APTX) | 0.0 | $300k | 539k | 0.56 |
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021
- Orbimed Advisors 2021 Q1 filed May 17, 2021
- Orbimed Advisors 2020 Q4 filed Feb. 16, 2021
- Orbimed Advisors 2020 Q3 filed Nov. 16, 2020
- Orbimed Advisors 2020 Q2 filed Aug. 14, 2020
- Orbimed Advisors 2020 Q1 filed May 15, 2020
- Orbimed Advisors 2019 Q4 filed Feb. 14, 2020
- Orbimed Advisors 2019 Q3 filed Nov. 14, 2019
- Orbimed Advisors 2019 Q2 filed Aug. 14, 2019
- Orbimed Advisors 2019 Q1 filed May 15, 2019
- Orbimed Advisors 2018 Q4 filed Feb. 14, 2019
- Orbimed Advisors 2018 Q3 filed Nov. 14, 2018